Long Non-Coding RNAs Expression in Breast Cancer: CBR3-AS1 LncRNA as a Sensitive Biomarker

Torkashvand, Safora; Basi, Ali; Ajdarkosh, Hossein; Rakhshani, Nasser; Nafisi, Nahid; Mowla, Seyed Javad; Moghadas, Ayda; Mohammadipour, Mahshid; Karbalaie Niya, Mohammad Hadi

doi:10.31557/APJCP.2021.22.9.2897

Long Non-Coding RNAs Expression in Breast Cancer: CBR3-AS1 LncRNA as a Sensitive Biomarker

Document Type : Research Articles

Authors

¹ Kasra Hospital, Tehran University of Medical Sciences, Tehran, Iran.

² Department of Oncology, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran.

³ Gastrointestinal and Liver Diseases Research Center, Iran University of Medical Sciences, Tehran, Iran.

⁴ Department of Internal Medicine, Iran University of Medical Sciences, Tehran, Iran.

⁵ Rasool Akram Medical Complex Clinical Research Development Center (RCRDC), Iran university of medical science Tehran, Iran.

⁶ Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran.

⁷ Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran.

10.31557/APJCP.2021.22.9.2897

Abstract

Background: Long non-coding RNAs (LncRNAs) are eminent genes in the human genome that interfere with the regulation of many complexities of organisms and control many of the various biological processes. As a result, it is considered that they may play an important role in different cancers. With regard to the high prevalence of breast cancer and the role of lncRNA, the present study aimed at investigating the expression of various lncRNAs. Method: Fresh tissues were obtained from operating rooms of Shariati, Khatamolanbia, and Milad Hospitals (Tehran, Iran) by a surgeon. A total of 45 tumor samples and 45 non-tumor samples (from the margin of tumor) were obtained from the same patients. Relative expression evaluation method was used in Real time PCR. Estrogenn receptor (ER), progesterone receptor (PR), and HER2 expression were analyzed using IHC analyses of each cell block. Results: Participants included 44 female and 1 male with the mean age ± SD of 50 ± 12.0 years (range: 23-74). A majority of participants (41/45) were Ductal carcinoma type. Our results showed significant expressions for CBR3-AS1 (P-value=0.0139), RAB6C-AS1 (P-value=0.0023), and ZEB2-AS1 (P-value=0.0289) in comparison with the healthy cells. ROC curve analysis for CBR3-AS1 LncRNA revaled sensitivity more than 70%. Conclusion: Although CBR3-AS1, RAB6C-AS1, and ZEB2-AS1 lncRNAs were found to have high expressions in the breast cancer cells, only CBR3-AS1 lncRNA has a high chance to be a breast cancer biomarker.

Keywords